Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancer

被引:0
|
作者
Roldan, Fiorella L. [1 ]
Falagario, Ugo Giovanni [2 ,3 ]
Olsson, Mats [2 ]
Salas, Rodolfo Sanchez [2 ]
Aly, Markus [2 ,4 ]
Egevad, Lars [5 ]
Lantz, Anna [2 ,4 ]
Gronberg, Henrik [4 ]
Akre, Olof [2 ]
Hosseini, Abolfazl [2 ,6 ,7 ]
Wiklund, N. Peter [2 ,8 ]
机构
[1] Hosp Clin Barcelona, Serv Urol, Barcelona, Spain
[2] Karolinska Inst, Dept Mol Med & Surg, Sect Urol, Stockholm, Sweden
[3] Univ Foggia, Dept Urol & Organ Transplantat, Viale Luigi Pinto 1, I-71122 Foggia, FG, Italy
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[6] Danderyd Hosp, Dept Urol, Stockholm, Sweden
[7] Univ Hosp, Dept Urol, Basel, Switzerland
[8] Icahn Sch Med, Dept Urol, Mt Sinai Hlth Syst, New York, NY USA
来源
BJUI COMPASS | 2024年 / 5卷 / 09期
关键词
cancer-specific survival; cystoprostatectomy; locally advanced prostate cancer; radical pelvic surgery; radiotherapy; CYSTOPROSTATECTOMY; RADIOTHERAPY; MORTALITY; THERAPY; VOLUME; TRIAL;
D O I
10.1002/bco2.414
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveThe aim of this study is to evaluate treatment patterns and long-term oncological outcomes of patients with locally advanced prostate cancer (LAPCa).Patients and methodsThis is a population-based study including LAPC (cT3-4, M0) patients from the Stockholm region (Sweden). A sub-analysis was performed in men treated with primary cystoprostatectomy or total pelvic exenteration (TPE) for cT4 prostate cancer (PCa). Cox regression was used to identify predictors of overall mortality (OM) and cancer-specific mortality (CSM). Biochemical progression-free survival (BPFS) and 90 days complications were reported for the radical surgery subgroup.Patients and methodsThis is a population-based study including LAPC (cT3-4, M0) patients from the Stockholm region (Sweden). A sub-analysis was performed in men treated with primary cystoprostatectomy or total pelvic exenteration (TPE) for cT4 prostate cancer (PCa). Cox regression was used to identify predictors of overall mortality (OM) and cancer-specific mortality (CSM). Biochemical progression-free survival (BPFS) and 90 days complications were reported for the radical surgery subgroup.ResultsWe included 2921 patients with cT3(N = 2713) or cT4(N = 208), M0 PCa diagnosed between 2003 and 2019. Out of these, 249(9%), 1497(51%) and 1175(40%) underwent radical prostatectomy, RT + ADT and androgen deprivation therapy (ADT), respectively. Survival rates were 76% (IQR: 68, 83), 47% (IQR: 44, 50) and 23% (IQR: 20, 27), respectively at 10 years. Irrespective of treatment modalities, cT4 patients had worse survival compared to cT3 patients (OM: HR1.44, IQR:1.17,1.77; PCSM: HR1.39, IQR:1.06,1.82). Twenty-seven patients with cT4, N0-1, M0 were treated with cystoprostatectomy or TPE. Twenty-two patients (81.5%) received neoadjuvant ADT. The 5-year BPFS, CSS and OS rates were 39.6%, 68.8% and 63.8%, respectively. Nine patients (33.3%) had Clavien-Dindo grade III and 1 (3.7%) grade IV complication within 90 days after surgery.ConclusionsPelvic surgery with radical intent as part of a multidisciplinary management may be an effective alternative for selected patients with locally advanced PCa leading to local tumour control and an acceptable morbidity.
引用
收藏
页码:885 / 892
页数:8
相关论文
共 50 条
  • [21] The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes
    Milonas, Daimantas
    Venclovas, Zilvinas
    Sasnauskas, Gustas
    Ruzgas, Tomas
    CANCERS, 2021, 13 (10)
  • [22] Long-Term Outcomes after Double Free Flap Reconstruction for Locally Advanced Head and Neck Cancer
    Brinkman, J. Nick
    Kambiz, Shoista
    de Jong, Tim
    Mureau, Marc A. M.
    JOURNAL OF RECONSTRUCTIVE MICROSURGERY, 2019, 35 (01) : 66 - 73
  • [23] Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer
    Choi, Moon Hyung
    Oh, Soon Nam
    Lee, In Kyu
    Oh, Seong Taek
    Won, Daeyoun David
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2018, 9 (01) : 53 - 59
  • [24] TREATMENT VARIABILITY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER IN THE UNITED STATES AND ITS EFFECT ON LONG-TERM OUTCOMES
    Barbetta, Arianna
    Lidor, Anne O.
    Gennarelli, Renee L.
    Elkin, Elena
    Bott, Matthew
    Isbell, James
    Bains, Manjit S.
    Jones, David R.
    Molena, Daniela
    GASTROENTEROLOGY, 2017, 152 (05) : S1216 - S1216
  • [25] Multimodal therapy of locally advanced prostate cancer
    Heidenreich, A.
    Boehmer, D.
    UROLOGE, 2016, 55 (03): : 333 - 344
  • [26] Multimodal treatment of high-risk and locally advanced prostate cancer
    Preisser, Felix
    Tilki, Derya
    UROLOGIE, 2022, 61 (12): : 1341 - 1344
  • [27] ONCOLOGICAL RESULTS OF RADICAL SURGICAL TREATMENT IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
    Loran, O. B.
    Veliyev, E. I.
    Kotov, S. V.
    ONKOUROLOGIYA, 2009, 5 (03): : 29 - 34
  • [28] Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation
    Luo, Hua-chun
    Cheng, Li-ping
    Cheng, Hui-hua
    Fu, Zhi-chao
    Liao, Shao-guang
    Li, Dong-shi
    Zheng, Wen-fa
    Lin, Gui-shan
    Zhu, Jin-feng
    Xu, Jian-feng
    Yin, Qin
    Yu, Qing-yang
    MEDICAL ONCOLOGY, 2014, 31 (06)
  • [29] Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation
    Hua-chun Luo
    Li-ping Cheng
    Hui-hua Cheng
    Zhi-chao Fu
    Shao-guang Liao
    Dong-shi Li
    Wen-fa Zheng
    Gui-shan Lin
    Jin-feng Zhu
    Jian-feng Xu
    Qin Yin
    Qing-yang Yu
    Medical Oncology, 2014, 31
  • [30] Long-term outcomes of 60 gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer
    Hashine, K
    Numata, K
    Azuma, K
    Sumiyoshi, Y
    Kataoka, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (11) : 655 - 659